SomaLogic Announces June Conference Participation

BOULDER, Colo., June 01, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the following conferences.

• Jefferies Healthcare ConferenceJune 8-9, 2022, in New York

• 7th Annual MarketsandMarkets Biomarker and Companion Diagnostics ConferenceJoe Gogain, Director, Clinical R&D will present “Bigger data = better data. Detect 7,000 proteins at once with high throughput to optimize biomarker discover” during a session on June 16, 2022, in San Diego, CA.

• MultiOmics in Precision MedicineAngela Bakker-Lee, Executive Vice President, Healthcare Strategy will moderate a panel titled, “Precision medicine for type 2 diabetes – using proteomics and AI to screen at-risk patients for major cardiac events” on June 22, 2022, at the Broad Institute in Boston.

• Precision Medicine World Conference (PMWC)Steve Williams, Chief Medical Officer will participate in a session titled, “Advances in Proteomics – Stratifying cardiovascular risk to decrease cost of care” on June 28, 2022, in Santa Clara, CA.

• Cowen Tools/Dx RevolutionRoy Smythe, Chief Executive Officer will participate in a panel titled, “Just Add Omics: Implications for a shift towards multi-modality and multi-analyte approaches to life science research and clinical applications” on June 28, 2022, in Boulder, CO.

About SomaLogicSomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.

The SomaScan® Platform is for Research Use Only (RUO) and has not been cleared or approved by the U.S. Food and Drug Administration for diagnostic or patient management purposes.

Investor ContactLauren Glaser[email protected]

Marissa BychGilmartin Group LLC[email protected]

Media ContactEmilia Costales720-798-5054[email protected]

You May Also Be Interested In